A Different Approach to Validating Screening Assays for Developmental Toxicity

被引:43
作者
Daston, George P. [1 ]
Chapin, Robert E. [2 ]
Scialli, Anthony R. [3 ]
Piersma, Aldert H. [4 ]
Carney, Edward W. [5 ]
Rogers, John M. [6 ]
Friedman, Jan M. [7 ,8 ]
机构
[1] Procter & Gamble Co, Cincinnati, OH 45202 USA
[2] Pfizer Global R&D, Groton, CT USA
[3] Tetra Tech Sci, Arlington, VA USA
[4] RIVM, Bilthoven, Netherlands
[5] Dow Chem Co USA, Midland, MI 48674 USA
[6] US EPA, Tox Assessment Div, NHEERL, ORD, Res Triangle Pk, NC 27711 USA
[7] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
[8] Child & Family Res Inst, Vancouver, BC, Canada
关键词
in vitro methods; validation; developmental toxicity; VITRO EMBRYOTOXICITY TESTS; IN-VITRO; EMBRYO CULTURE; RAT; PREDICTION; CHEMICALS; SELECTION; WORKSHOP;
D O I
10.1002/bdrb.20276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: There continue to be many efforts around the world to develop assays that are shorter than the traditional embryofetal developmental toxicity assay, or use fewer or no mammals, or use less compound, or have all three attributes. Each assay developer needs to test the putative assay against a set of performance standards, which traditionally has involved testing the assays against a list of compounds that are generally recognized as "positive'' or "negative'' in vivo. However, developmental toxicity is highly conditional, being particularly dependent on magnitude (i.e. dose) and timing of exposure, which makes it difficult to develop lists of compounds neatly assigned as developmental toxicants or not. APPROACH: Here we offer an alternative approach for the evaluation of developmental toxicity assays based on exposures. Exposures are classified as "positive'' or "negative'' in a system, depending on the compound and the internal concentration. Although this linkage to "internal dose'' departs from the recent approaches to validation, it fits well with widely accepted principles of developmental toxicology. CONCLUSIONS: This paper introduces this concept, discusses some of the benefits and drawbacks of such an approach, and lays out the steps we propose to implement it for the evaluation of developmental toxicity assays. Birth Defects Res (Part B) 89: 526-530, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:526 / 530
页数:5
相关论文
共 18 条
  • [1] Selection of test chemicals for the ECVAM international validation study on in vitro embryotoxicity tests
    Brown, NA
    [J]. ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2002, 30 (02): : 177 - 198
  • [2] Christian MS, 2001, TERATOLOGY, V64, P51, DOI 10.1002/tera.1047
  • [3] EVALUATION OF CHICK-EMBRYO NEURAL RETINA CELL-CULTURE AS A SCREEN FOR DEVELOPMENTAL TOXICANTS
    DASTON, GP
    BAINES, D
    ELMORE, E
    FITZGERALD, MP
    SHARMA, S
    [J]. FUNDAMENTAL AND APPLIED TOXICOLOGY, 1995, 26 (02): : 203 - 210
  • [4] INTERSPECIES COMPARISONS OF A/D RATIOS - A/D RATIOS ARE NOT CONSTANT ACROSS SPECIES
    DASTON, GP
    ROGERS, JM
    VERSTEEG, DJ
    SABOURIN, TD
    BAINES, D
    MARSH, SS
    [J]. FUNDAMENTAL AND APPLIED TOXICOLOGY, 1991, 17 (04): : 696 - 722
  • [5] The ECVAM international validation study on in vitro embryotoxicity tests:: Results of the definitive phase and evaluation of prediction models
    Genschow, E
    Spielmann, H
    Scholz, G
    Seiler, A
    Brown, N
    Piersma, A
    Brady, M
    Clemann, N
    Huuskonen, H
    Paillard, F
    Bremer, S
    Becker, K
    [J]. ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2002, 30 (02): : 151 - 176
  • [6] Use of the rat postimplantation embryo culture to assess the embryotoxic potency within a chemical category and to identify toxic metabolites
    Janer, G.
    Verhoeff, A.
    Gilsing, H. D.
    Piersma, A. H.
    [J]. TOXICOLOGY IN VITRO, 2008, 22 (07) : 1797 - 1805
  • [7] JOHNSON EM, 1982, TERATOGEN CARCIN MUT, V2, P263, DOI 10.1002/1520-6866(1990)2:3/4<263::AID-TCM1770020308>3.0.CO
  • [8] 2-I
  • [9] A Review of the Implementation of the Embryonic Stem Cell Test (EST) The report and recommendations of an ECVAM/ReProTect Workshop
    Marx-Stoelting, Philip
    Adriaens, Els
    Ahr, Hans-Juergen
    Bremer, Susanne
    Garthoff, Bernward
    Gelbke, Heinz-Peter
    Piersma, Aldert
    Pellizzer, Cristian
    Reuter, Ulrike
    Rogiers, Vera
    Schenk, Barbara
    Schwengberg, Silke
    Seiler, Andrea
    Spielmann, Horst
    Steemans, Margino
    Stedman, Donald B.
    Vanparys, Philippe
    Vericat, Joan Albert
    Verwei, Miriam
    van de Water, Femke
    Weimer, Marc
    Schwarz, Michael
    [J]. ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2009, 37 (03): : 313 - 328
  • [10] NISHIMURA M, 1982, ARZNEIMITTELFORSCH, V32-2, P1518